Compare Aon PLC (AON) vs Novo Nordisk A/S (NVO) Price & Performance

Aon PLCTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Aon PLC vs Novo Nordisk A/S — how do they compare? Aon PLC trades at $357.49 (market cap $76.23B), while Novo Nordisk A/S trades at $49.17 (market cap $216.71B). The key difference: Novo Nordisk A/S is far larger — about 2.8× Aon PLC's market cap, and Novo Nordisk A/S pays the higher dividend (3.64%). Which is the better fit depends on your goals.

	AON	NVO
Market Cap	$76.23B	$216.71B
Sector	Financials	Health
52-Week High	$375.27	$71.70
52-Week Low	$308.22	$35.29
Enterprise Value	$90.29B	$235.67B
Dividend Yield	0.92%	3.64%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aon PLC

AON trades at $356.94, up 0.39% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with Q1 2026 EPS of $6.48 beating expectations and revenue growth from $17.18B in 2025 to projected $17.5B in 2026. Net income margin improved to 22.54% with robust ROE of 46.82%. Recent news highlights dividend declarations and upcoming Q2 earnings.

AON presents a compelling investment case with consistent earnings beats, strong profitability metrics, and analyst consensus target of $399.67 offering 12% upside. Risks include elevated valuation multiples and debt levels, while institutional sentiment remains positive with 50% buy ratings. The stock's technical strength and fundamental growth support continued upward momentum.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $49.48, up 1.23% today, with a bullish technical signal from moving averages and strong fundamentals including a 37.2% net income margin and 71.4% ROE. Recent earnings beats in Q3 2025-Q1 2026 highlight operational strength, while cash flow remains positive at $10.81B in 2025. The stock benefits from GLP-1 drug leadership, with oral Wegovy driving market expansion amid competitive pressures.

Outlook is positive with analyst consensus at 57.9% buy ratings, but risks include prescription slowdown concerns and rising debt-to-asset ratio to 22.54 in 2025. Investment appeal lies in robust profitability and growth in obesity/diabetes treatments, though investors should monitor competition and execution on guidance.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AON

Aon declares quarterly cash dividend of $0.82 per share payable August 14, 2026.PRNewsWire · 2 days agoBullish Aon to release Q2 2026 earnings on July 29 with live CEO and CFO call.PRNewsWire · 2 days agoNeutral View details →

NVO

Vivani develops semaglutide implant to improve long-term weight loss adherence for GLP-1 usersCNBC · 2 days agoBullish Novo Nordisk's Wegovy pill leads obesity treatment, challenging Eli Lilly with superior efficacy and fewer restrictions.Seeking Alpha · 4 days agoBullish Novo Nordisk remains a Buy despite recent stock drop, offering strong long-term growth and portfolio diversification.Seeking Alpha · 4 days agoBullish View details →

About Aon PLC

Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.